Skip to main content

Advertisement

Table 3 Summary of studies focusing on the efficacy of antiemetic therapy in patients receiving MEC

From: Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy

Author Regimen (mg) Acute CR (%) Delayed CR (%) Overall CR (%) Chemotherapy
Eisenberg et al. (2003) Palo (0.25) 63 54 46 MEC
Palo (0.75) 57.1 56.6 47.1
Celio et al. (2011) Palo (0.25) + Dex (8) day 1 88.6 68.7 67.5 MEC
Palo (0.25) + Dex (8) days 1-3 84.3 77.7 71.1
Tanioka et al. (2013) Gra (1) + Dex (12) + Ap 97.8 62.2 62.2 CBDCA-based
Gra (1) + Dex(12) 95.7 52.2 52.2
Hesketh et al. (2016) Gra (2) day1-3 + Dex (20) + Rol (180) 91.7 82.3 80.2 CBDCA-based
Gra (2 mg) days1-3 + Dex (20 mg) 88.0 65.6 64.6
Yahata et al. (2016) Gra (1/4) + Dex (20) + Ap 94.0 63.6 61.6 CBDCA + PAC
Gra (1/4) + Dex (20) 90.4 49.3 47.3
Present study Palo (0.75) + Dex (9.9) + Ap 100 91.9 91.9 CBDCA-based
  1. Doses of Ap were the standard doses recommended by various guidelines such as 125 mg on day 1 and 80 mg on days 2 and 3. “MEC” in the chemotherapy column indicates that the MEC was not specified
  2. CR complete response, Palo palonosetron, Gra granisetron, Dex dexamethasone, Ap aprepitant, Rol rolapitant, MEC moderately emetogenic chemotherapy, CBDCA carboplatin, PAC paclitaxel